Table 3. Antimicrobial Activity of Isolated Compounds against ESKAPE Bacteria at 100 μg/mL.
| growth inhibition (%) |
|||||
|---|---|---|---|---|---|
| compound | VSEFe | VREFe | MSSAe | MRSAe | ECe |
| 17-deoxy-aspergillin PZ (1) | 11.8 | 27.7 | 28.1 | ||
| aspergillin PZ (2) | 23.0 | 9.0 | |||
| aspochalasin D (3) | 37.2 | 23.8 | 81.4 | 87.2 | |
| asperphenamate (4) | 10.4 | 62.9 | 22.5 | ||
| N-benzoyl-l-phenylalaninol (5) | 13.3 | 50.7 | |||
| 2-O-methylbutyrolactone II (6) | |||||
| sydonic acid (8) | 34.0 | 11.9 | |||
| asterriquinol D dimethyl ether (10) | 50.9 | 62.3 | 48.2 | ||
| O-methylmellein (11) | 16.2 | ||||
| atranone A (12) | 13.0 | 6.0 | |||
| atranone B (13) | 12.2 | ||||
| stachybotrolide acetate (14)d | 81.0 | 92.9 | 21.5 | ||
| stachybotrydial acetate (15) | 82.7 | 89.3 | 18.3 | ||
| stachybotrolide (16) | 82.2 | 91.2 | 23.7 | ||
| penicillic acid (17) | 80.4 | 51.4 | |||
| 5,6-dihydropenicillic acid (18) | 38.3 | ||||
| MIC positive control in μg/mL. | 3.75a | 25.0a | 200.0b | 2.5a | 0.5c |
a
Vancomycin - Inactive at 100 μg/mL.
b
Ampicillin - Inactive at 100 μg/mL.
c
Gentamicin - Inactive at 100 μg/mL.
d
Tested at 10 μg/mL.
e
VSEF, vancomycin-susceptible E. faecalis ATCC 29212; VREF, vancomycin-resistant E. faecalis ATCC 51299; MSSA, methicillin-susceptible S. aureus ATCC 25923; MRSA, methicillin-resistant S. aureus ATCC 43300; and EC, E. cloacae ATCC 700323.